Senhwa Biosciences begins patient dosing in NCI-sponsored pilot study of Pidnarulex pharmacodynamics in patients with advanced solid tumours: Taipei, Taiwan Thursday, July 17, 202 ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug ...

Researchers at The Wistar Institute have found that FDA-approved cancer drugs known as PARP1 inhibitors can effectively stop the growth of lymphomas driven by the Epstein-Barr virus (EBV), ...

Precancerous cells must adapt to and overcome cellular stress and inflammation in order to progress and form malignant tumors. Now, researchers at University of California San Diego School of Medicine ...

A new drug was shown to significantly reduce tumor growth in lab studies by up to 77% for melanoma and colorectal cancers.

Chemoresistance remains one of the most formidable challenges in effective cancer treatment, often leading to disease relapse, metastasis, and poor patient ...

The authors study how apolipoprotein L1 variants impact inflammation and lipid accumulation in macrophages. The findings will be useful for researchers investigating macrophage metabolism and ...

While much research focuses on oncogenic proteins and signaling pathways in aggressive cancers, fewer studies investigate how normal cells transform into ...